Microba Life Sciences LimitedASX: MAP

Q1 FY27 Quarterly Activities Report & Appendix 4C

· Issued by Microba Life Sciences Limited via ASX

Filed with ASX · · 11 pages · English

Summary by 6ix AI

Additionally, the company has implemented significant cost reductions and plans further measures to optimize its financial position. The report also discusses the company's cash flow situation, including a net operating cash outflow and plans for a capital raise through a placement.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/q1-fy27-quarterly-activities-report-and-appendix-4c-1

Watch Microba Life Sciences' latest callMicroba Life Sciences (ASX:MAP) Q4 2025 Earnings Call · Replay · Jul 22, 2025Read the transcript of Microba Life Sciences (ASX:MAP) Q4 2025 Earnings Call

Release

ASX Announcement 20 October 2026 Q1 FY27 Quarterly Activities Report & Appendix 4C Record core testing revenue, up 31% vs PCP; GI Navigator launched in Australia and the United Kingdom; cost base reset underway. Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a...

Microba Life Sciences Limited on 6ix

Story so far

Earlier from Microba Life Sciences

Later from Microba Life Sciences

All Microba Life Sciences news releases